RETRACTION: Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer

RETRACTION: Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer

To our readers: With deep regrets, we inform our Readers that the article Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer (DOI: http://dx.doi.org/10.4081/oncol.2014.236), which has been published Ahead of Print in the first issue of Oncolog...

Full description

Bibliographic Details
Main Author:	Camillo Porta
Format:	Article
Language:	English
Published:	PAGEPress Publications 2014-06-01
Series:	Oncology Reviews
Online Access:	http://www.oncologyreviews.org/index.php/or/article/view/255

Similar Items

RETRACTED - Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer
by: Yousif Abubakr, et al.
Published: (2014-03-01)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
by: Li Bian, et al.
Published: (2020-10-01)

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
by: Ajay Dhakal, et al.
Published: (2020-07-01)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
by: Anishka D’Souza, et al.
Published: (2018-06-01)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
by: Mariya Rozenblit, et al.
Published: (2021-01-01)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
by: Emilia Montagna, et al.
Published: (2019-12-01)

Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study
by: Ariane Mamguem Kamga, et al.
Published: (2021-10-01)

Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
by: Shaymaa Bahnassy, et al.
Published: (2020-09-01)

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
by: Aradhana Rani, et al.
Published: (2019-05-01)

Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression
by: Dingyong Wu, et al.
Published: (2021-02-01)

Everolimus in the Treatment of Metastatic Breast Cancer
by: Melanie E. Royce, et al.
Published: (2015-01-01)

Everolimus in the Treatment of Metastatic Breast Cancer
by: Melanie E. Royce, et al.
Published: (2015-09-01)

Efficacy of chemotherapy after hormone therapy for hormone receptor–positive metastatic breast cancer
by: Ryutaro Mori, et al.
Published: (2014-11-01)

Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
by: Berna Öksüzoğlu, et al.
Published: (2020-06-01)

Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer
by: Maithreyi Sarma, et al.
Published: (2020-12-01)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
by: Zongbi Yi, et al.
Published: (2020-08-01)

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
by: Norikazu Masuda, et al.
Published: (2021-08-01)

Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
by: Shimoi T, et al.
Published: (2018-02-01)

A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases
by: J. Thaddeus Beck, et al.
Published: (2015-02-01)

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies
by: John F. R. Robertson, et al.
Published: (2021-02-01)

Magnetic resonance imaging radiomics signatures for predicting endocrine resistance in hormone receptor-positive non-metastatic breast cancer
by: Yaping Yang, et al.
Published: (2021-12-01)

Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer – A retrospective pilot analysis and viewpoint
by: Jyoti Bajpai, et al.
Published: (2017-01-01)

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
by: Peter Schmid, et al.
Published: (2021-01-01)

Early Changes of the Standardized Uptake Values (SUV<sub>max</sub>) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
by: Marianna Sirico, et al.
Published: (2020-11-01)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
by: Naoto T. Ueno, et al.
Published: (2020-02-01)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
by: Zongbi Yi, et al.
Published: (2019-05-01)

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study
by: Raffaella Palumbo, et al.
Published: (2021-03-01)

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
by: Alba, E., et al.
Published: (2022)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
by: Lorenzo Rossi, et al.
Published: (2019-05-01)

Metastatic breast cancer: Endocrine therapy landscape reshaped
by: Mohamad Adham Salkeni, et al.
Published: (2017-10-01)

Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
by: L Yu Vladimirova
Published: (2016-12-01)

Optimal management of hormone receptor positive metastatic breast cancer in 2016
by: Tomas Reinert, et al.
Published: (2015-11-01)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
by: Ami N Shah, et al.
Published: (2020-06-01)

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
by: Paplomata E, et al.
Published: (2013-01-01)

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
by: Yun Wu, et al.
Published: (2021-02-01)

The predictive ability of plasma ESR 1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer
by: Du YF, et al.
Published: (2018-09-01)

Surgery Should Complement Endocrine Therapy for Elderly Postmenopausal Women with Hormone Receptor-Positive Early-Stage Breast Cancer
by: Olivier Nguyen, et al.
Published: (2012-01-01)

Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
by: Katsuhiko Nakatsukasa, et al.
Published: (2021-01-01)

Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
by: Le-Sang Shen, et al.
Published: (2020-05-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)